Clare Kahn
CIK: 0001849236
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Discretionary Trading P&L
Holdings
Transaction History (4 total)
- Jun 10, 2026SLDB
Solid Biosciences Inc.
Award(A)DirectDirector Stock Option (Right to Buy)
77.5K shares- - Apr 3, 2026STOK
Stoke Therapeutics, Inc.
Award(A)DirectStock Option (Right to Buy)
30.8K shares- - Jun 12, 2025SLDB
Solid Biosciences Inc.
Award(A)DirectDirector Stock Option (Right to Buy)
77.5K shares- - Mar 11, 2025SLDB
Solid Biosciences Inc.
Purchase(P)Direct1.9K shares at avg. $5.34$10K
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Jun 10, 2026 |  SLDB Solid Biosciences Inc. | Award(A) Director Stock Option (Right to Buy) | 77,500 | - | - | Direct |
| Apr 3, 2026 |  STOK Stoke Therapeutics, Inc. | Award(A) Stock Option (Right to Buy) | 30,782 | - | - | Direct |
| Jun 12, 2025 | SLDB Solid Biosciences Inc. | Award(A) Director Stock Option (Right to Buy) | 77,500 | - | - | Direct |
| Mar 11, 2025 | SLDB Solid Biosciences Inc. | Purchase(P) | 1,860 | $5.34 | $9,924 | Direct |
1-4 of 4 transactions
About Kahn Clare
Kahn Clare (SEC CIK 0001849236) files insider reports with the SEC as Director of Solid Biosciences Inc. (SLDB) and Director of Stoke Therapeutics, Inc. (STOK).
Signal8 holds 5 ownership filings by Kahn Clare (1 Form 3, 4 Form 4), filed between Mar 13, 2025 and Jun 11, 2026. Those filings report 4 transactions, from Mar 11, 2025 to Jun 10, 2026. Signal8's Form 4 history starts in Sep 2024.
The business address on Kahn Clare's filings is in CHARLESTOWN, MA.
Recent filings by Kahn Clare
Other insiders filing for Solid Biosciences Inc. (SLDB)
- Ganot Ilan, Director
- Brooks Gabriel, Chief Medical Officer
- SMITH IAN F, Director
- RA CAPITAL MANAGEMENT, L.P., 10% Owner
- Nagendran Sukumar, Director
- PERCEPTIVE ADVISORS LLC, Director